These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31602625)

  • 1. From Yeast to Humans: Leveraging New Approaches in Yeast to Accelerate Discovery of Therapeutic Targets for Synucleinopathies.
    Piotrowski JS; Tardiff DF
    Methods Mol Biol; 2019; 2049():419-444. PubMed ID: 31602625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yeast-Based Screens to Target Alpha-Synuclein Toxicity.
    Brás IC; Popova B; Braus GH; Outeiro TF
    Methods Mol Biol; 2019; 1948():145-156. PubMed ID: 30771176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From yeast to patient neurons and back again: powerful new discovery platform.
    Tardiff DF; Khurana V; Chung CY; Lindquist S
    Mov Disord; 2014 Sep; 29(10):1231-40. PubMed ID: 25131316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons.
    Tardiff DF; Jui NT; Khurana V; Tambe MA; Thompson ML; Chung CY; Kamadurai HB; Kim HT; Lancaster AK; Caldwell KA; Caldwell GA; Rochet JC; Buchwald SL; Lindquist S
    Science; 2013 Nov; 342(6161):979-83. PubMed ID: 24158909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A small molecule autophagy inducer exerts cytoprotection against α-synuclein toxicity.
    Suresh SN; Manjithaya R
    Eur J Pharmacol; 2019 Nov; 862():172635. PubMed ID: 31491404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular models of alpha-synuclein toxicity and aggregation.
    Delenclos M; Burgess JD; Lamprokostopoulou A; Outeiro TF; Vekrellis K; McLean PJ
    J Neurochem; 2019 Sep; 150(5):566-576. PubMed ID: 31265132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies.
    Moussaud S; Malany S; Mehta A; Vasile S; Smith LH; McLean PJ
    Expert Opin Ther Targets; 2015 May; 19(5):589-603. PubMed ID: 25785645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting Stearoyl-CoA Desaturase Ameliorates α-Synuclein Cytotoxicity.
    Vincent BM; Tardiff DF; Piotrowski JS; Aron R; Lucas MC; Chung CY; Bacherman H; Chen Y; Pires M; Subramaniam R; Doshi DB; Sadlish H; Raja WK; Solís EJ; Khurana V; Le Bourdonnec B; Scannevin RH; Rhodes KJ
    Cell Rep; 2018 Dec; 25(10):2742-2754.e31. PubMed ID: 30517862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ɑ-Synuclein strains and the variable pathologies of synucleinopathies.
    Peelaerts W; Baekelandt V
    J Neurochem; 2016 Oct; 139 Suppl 1():256-274. PubMed ID: 26924014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic screens for compounds that target the cellular pathologies underlying Parkinson's disease.
    Tardiff DF; Lindquist S
    Drug Discov Today Technol; 2013; 10(1):e121-8. PubMed ID: 24050240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized CRISPR-Cas Transcriptional Perturbation Screening Reveals Protective Genes against Alpha-Synuclein Toxicity.
    Chen YC; Farzadfard F; Gharaei N; Chen WCW; Cao J; Lu TK
    Mol Cell; 2017 Oct; 68(1):247-257.e5. PubMed ID: 28985507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular models as tools for the study of the role of alpha-synuclein in Parkinson's disease.
    Lázaro DF; Pavlou MAS; Outeiro TF
    Exp Neurol; 2017 Dec; 298(Pt B):162-171. PubMed ID: 28526239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-Scale Networks Link Neurodegenerative Disease Genes to α-Synuclein through Specific Molecular Pathways.
    Khurana V; Peng J; Chung CY; Auluck PK; Fanning S; Tardiff DF; Bartels T; Koeva M; Eichhorn SW; Benyamini H; Lou Y; Nutter-Upham A; Baru V; Freyzon Y; Tuncbag N; Costanzo M; San Luis BJ; Schöndorf DC; Barrasa MI; Ehsani S; Sanjana N; Zhong Q; Gasser T; Bartel DP; Vidal M; Deleidi M; Boone C; Fraenkel E; Berger B; Lindquist S
    Cell Syst; 2017 Feb; 4(2):157-170.e14. PubMed ID: 28131822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting α-synuclein: Therapeutic options.
    Dehay B; Decressac M; Bourdenx M; Guadagnino I; Fernagut PO; Tamburrino A; Bassil F; Meissner WG; Bezard E
    Mov Disord; 2016 Jun; 31(6):882-8. PubMed ID: 26926119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
    Henderson MX; Trojanowski JQ; Lee VM
    Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations Between APOE Variants, Tau and α-Synuclein.
    Rodriguez-Vieitez E; Nielsen HM
    Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
    Vekrellis K; Stefanis L
    Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posttranslational Modifications and Clearing of α-Synuclein Aggregates in Yeast.
    Popova B; Kleinknecht A; Braus GH
    Biomolecules; 2015 Apr; 5(2):617-34. PubMed ID: 25915624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
    Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
    Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.